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Abstract 
Serum was analyzed from 146 healthy adult volunteers in eastern Africa to evaluate 
measles virus (MV) and canine distemper virus (CDV) neutralizing antibody (nAb) 
prevalence and potency. MV plaque reduction neutralization test (PRNT) results 
indicated that all sera were positive for MV nAbs. Furthermore, the 50% neutralizing 
dose (ND50) for the majority of sera corresponded to antibody titers induced by MV 
vaccination. CDV nAbs titers were low and generally were detected in sera with high 
MV nAb titers. A mutant virus was generated that was less sensitive to neutralization by 
human serum. The mutant virus genome had 10 nucleotide substitutions, which coded 
for single amino acid substitutions in the fusion (F) and hemagglutinin (H) glycoproteins 
and two substitutions in the large polymerase (L) protein. The H substitution occurred in 
a conserved region involved in receptor interactions among morbilliviruses, implying that 
this region is a target for cross-reactive neutralizing antibodies.  
 
Key words: canine distemper virus, measles virus, plaque reduction neutralization test, 
neutralizing antibody, hemagglutinin, pre-existing immunity, cross-neutralization 
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Introduction 
Canine distemper virus (CDV) is a member of the Morbillivirus genus, which also 
includes measles virus (MV), rinderpest virus (RPV), peste des petits ruminants virus 
and morbilliviruses that infect aquatic mammals (Blixenkrone-Moller, 1993; Di Guardo et 
al., 2005). These related viruses generally each have a restricted natural host range. 
For example MV infects humans, RPV infects cattle and other even-toed ungulates, and 
CDV infects a variety of carnivorous animals. However, CDV infection has been 
observed in monkey colonies indicating that its host range can extend to primates (Qiu 
et al., 2011; Sakai et al., 2013a), but so far, there is no conclusive evidence linking CDV 
to human disease in spite of its speculative association to illness of unknown etiology 
(Rima and Duprex, 2006). Lab-adapted CDV has been injected into humans without 
causing symptoms of infection suggesting that humans are not a permissive host for the 
virus (Hoekenga et al., 1960), which is consistent with recent studies showing that 
mutations facilitating both entry and replication are needed for CDV to efficiently adapt 
to human cells (Otsuki et al., 2013; Sakai et al., 2013b). Prevalent MV immunity induced 
by universal vaccination or natural infections might also play a role in preventing CDV 
from crossing the human barrier (de Vries et al., 2014). Despite considerable 
characterization of antigenic and immunological relationships between CDV and MV 
(Haile et al., 1982; Orvell and Norrby, 1974, 1980; Stephenson and ter Meulen, 1979), 
CDV neutralizing antibodies (nAbs) in humans have not been extensively investigated.   
Morbilliviruses are attractive candidates for development of replication-competent 
vectors because modified live vaccines (e.g. MV, CDV, and RPV) have proven to be 
very safe and efficacious (Buczkowski et al., 2014), and promising preclinical results 
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have been generated with a number of experimental vectors (Brandler et al., 2007; 
Brandler and Tangy, 2008; Despres et al., 2005; Gauvrit et al., 2008; Guerbois et al., 
2009; Miest and Cattaneo, 2014; Wang et al., 2012). Morbilliviruses seem particularly 
relevant for development of replication-competent AIDS vaccine vectors since this 
genera of viruses replicates in lymphoid tissues like HIV (Draper and Heeney, 2010; 
Koff et al., 2013; Parks et al., 2013). Pre-existing MV immunity may interfere with use of 
MV vectors, and unlike other viral vector systems in which rare serotype viruses can be 
used as vector alternatives (Mingozzi et al., 2013; Santra et al., 2009), MV has just one 
serotype. Thus, CDV has been considered as a MV alternative to minimize the effect of 
widespread anti-MV antibodies (Miest et al., 2011; Zhang et al., 2013b). Because 
antibodies specific to MV do cross-react with CDV (Appel et al., 1984; de Vries et al., 
2014; Rima, 1983; Taylor et al., 1991), it is important to evaluate the prevalence and 
potency of CDV neutralizing activity in humans.   
In this study, 146 serum samples collected from healthy adults in three eastern Africa 
countries were surveyed for both MV and CDV nAbs. We found that MV nAbs were 
prevalent in these samples while the frequency of samples with significant CDV nAb 
titers was low. Moreover, when CDV neutralizing activity was detected, it correlated with 
high anti-MV titers. We also used human anti-serum to derive an in vitro escape mutant 
CDV strain with increased resistance to neutralization. Genomic sequence analysis of 
the resistant strain revealed an amino acid substitution in a conserved region of the MV 
and CDV hemagglutinin (H) proteins that may help identify the domain recognized by 
cross-reactive nAbs and aide in future design H variants that are less sensitive to the 
effect of anti-vector immunity.                 
Page 6 of 36 
 
 
 
Results:  
MV nAbs in African serum samples:  
Serum was collected from 146 healthy adult male and female volunteers between 19 
and 50 years of age (Table 1). The volunteers were participants in vaccine trial 
preparedness cohorts (Kamali, 2014) enrolled at 5 clinical research centers (CRCs) 
supported by IAVI in Kenya (Kilifi and Nairobi), Rwanda (Kigali), and Uganda (Masaka 
and Entebbe).  
The threshold for MV nAb positivity was defined as average ND50 titer of naïve 
macaque serum plus 3 times standard deviation. When the PRNT was performed with 
the naïve macaque serum control, the threshold was calculated as 8.63. All serum 
samples from African volunteers were positive for MV nAbs since their titers were above 
this threshold (Figure 1) and the ND50 values ranged from 16.0 to 6,270. For 
comparison, serum analyzed from a monkey vaccinated with an MV vaccine had an 
ND50 value of 1,446 and earlier studies in college students indicated that ND50 titers 
below 120 do not prevent measles (Chen et al., 1990). Overall, 77.4% of the African 
serum MV ND50 values fell between 120-2,000, which is approximately equivalent to 
300-5,000 milli-International Units (mIU) of WHO international standard MV antibodies 
(Cohen et al., 2007). The 300-5,000 mIU range is consistent with MV nAb levels 
induced by routine vaccination (Hussain et al., 2013; Leuridan et al., 2010), suggesting 
that these volunteers probably were vaccinated, although an MV vaccination history 
was not available to confirm this. Thirteen percent of the samples exhibited MV ND50 
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titers above 2,000, which was indicative of a stronger response than typically observed 
after vaccination suggesting that some volunteers had contracted measles at some 
point (Leuridan et al., 2010). No significant difference in ND50 titers was observed 
across gender or age groups. Overall antibody titers were similar among the regions 
except for Nairobi where volunteers exhibited significantly lower titers than other regions 
(p=0.01). 
Generally low CDV nAbs titers in African serum samples and their correlation with the 
magnitude of MV nAbs:  
When the CDV PRNT was performed with naïve ferret serum, the average CDV ND50 
titer plus 3 times standard deviation was determined to be 29.29, which we employed as 
our threshold for positivity. Based on this, approximately 33.6% of the African volunteer 
serum samples were negative. ND50 titers in 46.6% of the volunteers were between 
29.3-120 (Figure 2) and the remaining 19.8% had CDV ND50 titers above 120 but 
below 800. For comparison, serum from a ferret recently vaccinated with live-attenuated 
CDV was 33,551. Similar to MV nAbs, CDV ND50 titers were not significantly different 
across gender. With the exception of the volunteers from the Masaka CRC where 
higher CDV nAbs (p<0.001) were detected, no significant difference was observed for 
the other geographical regions. Although the CDV nAb titers overall were low, positive 
CDV nAb values generally correlated with higher magnitude MV titers (Figure 3A, 
Spearman’s ρ= 0.61, p<0.001). This relationship persisted when the correlation 
analyses were performed using nAb data that were stratified by volunteer enrollment 
site, gender, and age. Notably, the correlation did not significantly change when the 
analysis was performed without including data points from Masaka CRC in which the 
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volunteers had higher CDV nAb titers (Figure 3B, Spearman’s ρ= 0.63, p<0.001). This 
indicated that the correlation relationship between CDV and MV nAbs was general and 
was not due to this individual CRC. Given the lack of epidemiologic evidence to support 
frequent infection of CDV in humans, this result suggests that CDV neutralization is due 
to cross-neutralizing MV antibodies, which are present in low quantities and are 
detectable with the CDV PRNT only in volunteers with relatively high MV ND50 titers.    
A mutant CDV was generated that was more resistant to neutralization by human 
serum:  
To better understand the molecular basis of the cross-neutralization, a neutralization-
resistant CDV mutant was isolated and its genomic nucleotide sequence determined. 
The neutralization-resistant CDV mutant was selected using a single healthy adult 
donor serum of American origin that was available from a commercial source and had 
detectable CDV and MV nAbs. The neutralization-resistant CDV mutant grew in Vero 
cells with similar kinetics as the progenitor virus (data not shown) indicating that the 
escape mutation(s) had little effect on replication in culture. When the mutant was 
analyzed with the CDV PRNT using 25 serum samples randomly selected from the 
African volunteers, it was more resistant to neutralization in all sera tested. Across the 
25 samples, the ND50 titer determined with the mutant virus was decreased by 2.1 fold 
compared to the progenitor CDV (Figure 4).  
Genomic sequence analysis was performed on the resistant virus population and 10 
nucleotide substitutions were detected. Five of the substitutions were in protein coding 
sequences but were silent in terms of amino acid coding and one mutation was 
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detected in the trailer region (Table 2).   Four mutations caused amino acid coding 
changes with one in the fusion (F), one in the H and two in the large polymerase (L) 
proteins. The F gene mutation resulted in a tyrosine (Y) to serine (S) substitution at 
amino acid (aa) 48 in the signal peptide (Figure 5), while the H mutation resulted in a Y 
to aspartic acid (D) substitution at aa537 (Figure 6). The H amino acid substitution 
occurred in a region that is involved in virus receptor interactions and is conserved 
across morbilliviruses (Figure 6).  
The mouse monoclonal antibody 2F4 was used to confirm that the Y537D substitution 
altered antibody recognition in the receptor binding region. The 2F4 antibody is specific 
for the receptor binding region of MV H and is a potent neutralizer (Tahara et al., 2013). 
Stock concentration of the 2F4 antibody used in this study was 1.85 mg/ml and its 
neutralizing activity against MV was confirmed. When the antibody was tested in CDV 
PRNT, the dilution causing 50% neutralization was determined to be 1,017 and the 
calculated 50% inhibitory concentration (IC50) was 1.8 µg/ml based on this dilution 
(Figure 4B). In contrast, the 2F4 antibody had relatively little inhibitory effect on infection 
with the CDV mutant as shown by the significantly lower PRNT value of 39.7, which was 
equivalent to IC50 of 46.6 µg/ml. These results indicated that the Y to D substitution 
diminished binding by antibody 2F4 in the receptor-binding region, suggesting that the 
amino acid substitution had a similar effect on antibodies responsible for neutralization 
activity in human serum.     
 
 
Discussion:  
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Results from this study showed that anti-CDV neutralizing activity was relatively low or 
absent in sera from African clinical trial volunteers. To our knowledge, this is the first 
human serosurvey involving a large number of volunteers conducted to investigate the 
prevalence and potency of CDV nAbs. The results also indicated that CDV neutralizing 
activity likely was related to cross-reactive MV-specific antibodies. We analyzed a 
smaller number of American serum samples obtained from a commercial source and 
found their CDV neutralization potency was similarly low (data not shown). CDV nAbs 
have been reported before, for example in serum from subacute sclerosing 
panencephalitis  (SSPE) patients and in a small number of human samples, which were 
shown to weakly neutralize a MV-CDV chimeric virus (Miest et al., 2011; Sato et al., 
1973), but these studies were not designed to estimate the prevalence of anti-CDV 
neutralization. Our serosurvey results indicate that low level CDV nAbs can exist in a 
significant proportion of human populations probably induced by MV vaccination or 
infection. This contrasts with data from dogs, mice, and non-human primates vaccinated 
with live MV or vectors expressing MV F and H proteins in which detectable CDV nAbs 
were not elicited although MV vaccination prevented infection or disease progression 
following pathogenic CDV challenge (Appel et al., 1984; de Vries et al., 2014; Taylor et 
al., 1991; Wild et al., 1993). These results seem to suggest that MV vaccines induce 
human antibodies that can cross-neutralize CDV, but that this is less common in animal 
models.  
Among the 146 volunteers in the survey, 66.4% were positive for low CDV nAbs. This 
frequency of positivity suggests that MV vaccination or MV infection is the likely inducer 
of the CDV nAbs, although responses induced by CDV exposure cannot be ruled out. 
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Among the 5 CRCs in the survey, samples from the Masaka CRC had the highest CDV 
nAb titers. This may be related to the rural location of the Masaka site compared with 
the other 4 CRC locations. It is conceivable that rural locality could increase the risk of 
human CDV exposure due to a presence of unvaccinated domestic dogs and wild 
animal species that are occasionally infected by CDV during distemper outbreaks 
(Guiserix et al., 2007; Leisewitz et al., 2001; van de Bildt et al., 2002). The prevalence 
of higher titers in Masaka was not solely responsible for the association between high 
MV titers and CDV neutralizing antibodies as the same trend was seen if the Masaka 
data were omitted from the statistical analysis.     
The results showed that MV nAbs are prevalent since MV ND50 titers are all above the 
positive cutoff value of 8.63 that was calculated based on average titers of a negative 
monkey serum sample. In another study where PRNT was used for analysis of clinical 
human samples, a titer of 8 was found to be the threshold for detecting low levels of 
nAbs (Ratnam et al., 1995), which is similar to our cutoff value. Although all of the 
samples we analyzed were positive for MV antibodies, 9.6% had ND50 titers lower than 
120, which is the threshold for prevention of illness due to measles virus infection (Chen 
et al., 1990). If we assume that CDV ND50 titers greater than 120 are needed to inhibit 
infection with a vector based on CDV, then 80.2% of the African volunteers were below 
this threshold.   
Two amino acid substitutions were identified in the glycoproteins and two in the L 
protein of the CDV mutant that was selected for increased resistance to human serum 
neutralization. Because the membrane glycoproteins F and H are the only known 
targets of nAbs (Orvell and Norrby, 1974, 1980), the L mutations likely did not contribute 
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to neutralization resistance. The F amino acid substitution was located in the signal 
peptide that is present in the precursor protein but absent in mature form, and therefore 
was considered less likely to affect neutralization resistance (Plattet et al., 2007; von 
Messling et al., 2004). H gene diversity is common and often implicated in CDV 
evolution driven by immunologic pressure (Martella et al., 2006; Sekulin et al., 2011; 
Trebbien et al., 2014). The Y537D substitution in CDV H was located in a region that is 
conserved among morbilliviruses and corresponds to amino acid Y541 in MV H. This 
region of MV H contains residues involved in binding to cellular CD46 and Nectin, and is 
associated with antibody neutralization (Mateo et al., 2013; Santiago et al., 2010; 
Tahara et al., 2013; Zhang et al., 2013a). Due to high sequence identity in this H region, 
it is likely that nAbs induced by MV vaccination will bind the same domain in CDV H, 
and our data indicates that the Y to D substitution affected an epitope recognized by 
some cross-reactive nAbs in human serum. This conclusion agrees with our results with 
the MV H-specific monoclonal antibody 2F4, which we found to neutralize CDV but was 
significantly less active against the mutant virus. It was evident that the Y537D 
substitution did not abolish neutralization activity in human serum indicating that there 
were other binding sites recognized by nAbs, which is consistent with polyclonal nature 
of human antiserum against MV (Santibanez et al., 2005; Santibanez et al., 2002).    
The CDV H mutant might be useful for development of vaccine vectors or oncolytic 
agents because it is less sensitive to pre-existing MV-specific antibodies. Further 
characterization of the mutant H incorporated in a recombinant CDV will be required to 
determine if the Y537D substitution is stable during CDV propagation without constant 
application of selective pressure, if the substitution is attenuating, and whether it alters 
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receptor specificity. The general approach used to select the H mutant resistant to 
human serum may also be valuable for developing modified glycoproteins that are less 
susceptible to effects of anti-vector immunity.     
 
 
 
Materials and Methods:  
 
Cell and virus:  
Vero cells were used in the CDV or MV plaque reduction neutralization test (PRNT). 
The cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) 
supplemented with 10% fetal bovine serum. The CDV used was a clonal isolate derived 
from a commercial vaccine (Schering-Plough, USA) prepared from the live-attenuated 
Onderstepoort virus. Isolation and culture of the CDV mutant are described below. 
Neutralization sensitivity of the mutant CDV was assessed with a subset of the serum 
samples from clinical trial volunteers. MV used in these studies was an attenuated 
Edmonston strain derived from a commercial vaccine preparation (ATTENUVAX, 
MERCK & CO., USA). All three viruses were propagated in Vero cells and plaque 
forming units (PFU) were quantified as described previously for CDV (Zhang et al., 
2013b).      
 
Serum samples:  
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A total of 146 human serum samples were analyzed with the CDV and MV PRNT. 
These samples were collected from three eastern African countries from healthy adults, 
ages 19 to 50, enrolled in vaccine-trial preparatory studies to determine regional HIV 
incidence (Kamali, 2014). For CDV PRNT, sera from naïve and CDV-vaccinated ferrets 
served as negative and positive controls. Naïve and MV-vaccinated monkey sera were 
used for MV PRNT controls. All serum samples were inactivated at 56oC for 30 min 
before conducting the PRNT.     
 
CDV and MV PRNT:  
The PRNT was conducted with CDV, mutant CDV, or MV according to a standard MV 
PRNT protocol with slight modifications (Cohen et al., 2007). Notably, infections were 
performed using Vero monolayers instead of infecting cells in suspension. Briefly, four-
fold serial dilutions were made with each serum sample starting with a 1:4 dilution made 
by mixing 12.5 ul of serum with 37.5 ul of DMEM in duplicate wells in 96-well plates. 
The next dilution was made by transferring 12.5 ul of the diluted serum samples to 37.5 
ul of DMEM and so on. To each well of diluted serum, an equal volume (37.5 ul) of CDV 
or MV solution was added and incubated for 2 h. Thus, the first serum dilution on the 
plate was 1:8. For each experiment, either ferret or monkey sera were used as negative 
and positive controls and were processed in the same way as test samples. Vero cell 
monolayers were prepared one day before in 24-well plates and were approximately 
80% confluent the following day when they were fed with 0.2 ml of fresh medium. After 
mixtures of virus and diluted serum were incubated for 2 h to allow antibody binding, the 
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suspension (50 ul) was transferred from the 96-well plates to the 24-well plates 
containing Vero cell monolayers. Following 2 hour virus adsorption, the medium was 
removed and cells were fed with 1 ml DMEM containing 0.75% methylcellulose. Three 
days later, medium was removed and cells were washed once with PBS and then fixed 
with 100% cold methanol for 30 min. For viral plaque detection, the cells were incubated 
with a rabbit antiserum specific for CDV nucleoprotein or a commercial monoclonal 
antibody specific for MV nucleoprotein (AbCAM, USA). After removing the primary 
antibody, incubation was conducted with anti-rabbit or anti-mouse secondary antibodies 
conjugated with horse-radish peroxidase (HRP). Staining was performed by addition of 
3-Amino-9-ethylcarbazole (AEC) substrate for HRP (Sigma). Average plaque numbers 
were calculated from the duplicated wells at every dilution for each serum sample. For 
determining neutralization titers, the assay was standardized to generate about 30 
plaques per well when virus was treated without serum. At least four identical wells 
were infected with the virus only for generating an average plaque number in each 
experiment. Fifty percent neutralization dose (ND50) titers were defined as the 
reciprocal of the serum dilution at which the number of plaques is reduced to 50% 
relative to virus only controls. The calculation of ND50 titers followed the Karber formula 
as described for MV PRNT (Cohen et al., 2007).  The serum samples were considered 
positive for CDV or MV nAbs if the titers were greater than the average ND50 titer of the 
respective naïve ferret or monkey serum plus 3 times the standard deviation. 
The PRNT was conducted in the same way for the mouse monoclonal antibody 2F4 
except the starting dilution was 1:80 instead of 1:10 used in serum neutralization test 
due to limited antibody availability. The 2F4 antibody is specific to the receptor binding 
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region of MV H protein and is a potent neutralizer to MV (Tahara et al., 2013). 
Concentration of the antibody was 1.85 mg/ml before dilution. Fifty percent inhibitory 
concentration (IC50) was calculated for the 2F4 antibody according to dilutions needed 
to neutralize 50% CDV.   
 
Selection of neutralization escape mutants using human immune serum:  
Neutralization resistant CDV was isolated using a commercial human serum prepared 
from a single healthy adult donor in USA (Innovative Research, USA). The serum 
sample was positive for both MV and CDV neutralizing antibodies. A commercial human 
serum was used because sufficient quantity was available to make it possible to 
conduct serial virus passage in the presence of nAbs, and this also allowed us to 
preserve our limited quantities of serum from the African volunteers. For selecting CDV 
mutants that resisted neutralization, 1 x 106 PFU of CDV in 1 ml of culture medium was 
incubated with 200 µl of the undiluted serum in 37oC incubator for 1 h, after which the 
virus was added to a Vero cell monolayer cultured in T25 flask (Nunc, USA). After 1 h 
adsorption, the virus inoculum was replaced with 5 ml of cell culture growth medium that 
was supplemented with 5% human immune serum. Medium supernatant was harvested 
6 days later and 20% was used to infect a fresh monolayer that was subsequently 
incubated in medium containing 5% human immune serum. The supernatant was 
harvested when cytopathic effect (CPE) appeared. Virus passage in the presence of 
human serum was repeated 2 more times. After the 4th round of infection, virus was 
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analyzed with the PRNT using a subset of the African serum samples. The genomes of 
parental and mutant CDV were sequenced and compared.  
 
Analysis of CDV genomic nucleotide sequences:  
Genomic sequences were determined by extracting RNA from infected cell lysates, 
performing reverse transcription and PCR (RT-PCR) using primers based on the CDV 
nucleotide sequence in GenBank (accession number AF014953), and performing DNA 
sequencing on amplified DNA fragments. Overlapping sequences were assembled and 
anylyzed using Vector NTI (version 11.5, Life Technologies). Genomic sequences from 
CDV and the neutralization-resistant mutant were aligned with ClustalW program in 
Lasergene software (DNASTAR Inc.).  
 
Statistical analysis: 
Data analyses were conducted using Stata (v13.1, College Station, TX, USA). 
Spearman’s rank correlation analyses were performed to determine the relationship 
between CDV and MV nAb titers. Spearman’s correlation coefficient Rho and P values 
were given. The titers were transformed to Log10 expression for the correlation 
analyses and linear regression shown in Figure 3. To consider potential confounding 
geographical impact, CDV and MV nAb data were stratified and the correlation analyses 
were controlled for volunteer enrollment site, gender, and age at the time of blood 
sample draw.     
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Volunteer sex 
    
 
 
Male Female Volunteer age 
CRC Total N % N % Median Mean Min Max 
Kigali 30 14 46.7 16 53.3 27.5 30.2 20 50 
Masaka 30 20 66.7 10 33.3 36.5 36.7 23 48 
Kilifi 26 13 50.0 13 50.0 32.5 32.2 20 46 
Nairobi 30 17 56.7 13 43.3 26.5 29.0 20 41 
Entebbe 30 15 50.0 15 50.0 30.5 30.1 19 45 
Total 146 79 54.1 67 45.9 32.0 31.6 19 50 
 
 
Table 1. Demographic characteristics of volunteers involved in the study (n=146). CRC: 
Clinical Research Center. 
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Figure 1. Distribution of MV nAb titers. Negative threshold was defined as the average 
nAb titer of unvaccinated monkey serum plus 3 x standard deviation. Functional 
negative threshold was ND50 titer 120 since MV ND50 titers lower than that do not 
prevent measles (Chen et al., 1990). For the 146 volunteers, 90.4% had MV titers 
higher than 120 and majority of the titers were in ranges of 120.1-1,000 (61.0%) and 
1,000-2,000 (16.4%),  which correspond to MV antibodies induced by vaccinations 
(Hussain et al., 2013; Leuridan et al., 2010).  
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Figure 2. Distribution of CDV nAb titers. Negative threshold was defined as the average 
ND50 titer of unvaccinated ferret serum plus 3 x standard deviation. Total 80.2% of the 
volunteers had CDV ND50 titers either below the negative threshold or in 29.30-120 
range. 
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Figure 3. Strong correlation was found between MV and CDV nAb using Spearman’s 
rank correlation analysis. A. Correlation statistics from analyzing MV and CDV nAb titers 
of all 146 volunteers (Spearman’s coefficient Rho=0.61, p<0.001) suggest that CDV 
neutralization is due to cross-reactive MV nAbs that are present at low quantities in the 
volunteers who had relatively high MV nAb titers. Relationship between Log10 
transformed MV and CDV ND50 titers is shown by the fitted line. The shaded area 
represented 95% confidence interval of the fitted values. B. Analysis of the nAb values 
from the remaining 116 volunteers after excluding data points of Masaka CRC still 
showed a strong correlation between the MV and CDV nAb titers (Spearman’s 
coefficient Rho=0.63, p<0.001) and thus indicated that the observed correlation was 
general and was not due to the individual CRC in which the volunteers had relatively 
high level of CDV nAbs.   
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A. 
 
B. 
 
 
Figure 4. Neutralization of CDV and the neutralization-resistant mutant by human 
serum and mAb 2F4. A. ND50 titers of serum. Dots on the left represent 25 serum 
samples randomly selected from the 146 volunteers and the two lines represented 
mean ND50 values to each virus. The average ND50 titer to mutant CDV was 2.1 fold 
lower than that to CDV indicating the mutant CDV was more resistant to the serum 
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neutralization. B. IC50 of the 2F4 antibody. The bars represented concentrations of the 
2F4 antibody needed to neutralize 50% of the input CDV or the CDV mutant. The 
highest dilution of the monoclonal antibody causing 50% neutralization of CDV was 
1,017 and calculated IC50 was 1.8 µg/ml based on this dilution. In contrast, the maximal 
dilution to neutralize 50% of the mutant virus was only 39.7, which was equivalent to 
IC50 of 46.6 µg/ml, suggesting the Y to D substitution in the receptor binding site of H 
diminished the antibody binding.    
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Nucleotide differences between CDV and the neutralization resistant CDVa 
ntb     CDV Mutant CDV aa substitutionc 
M gene nt 3,432-4,439 
3,665 A G Silent 
3,707 A G Silent 
3,710 A G Silent 
F gene nt 4,935-6,923 
5,077 A C Y to S 
 H gene nt 7,079-8,902 
7,786 T A Silent 
8,687 T G Y to D 
 L gene nt 9,030-15,584 
11,455 A G Q to R 
14,298 A G I to V 
 14,324 C T Silent 
 
        Trailer nt 15,585-15,690 
 15,591     A G   N/A   
 
Table 2. Summary of nucleotide changes and amino acid substitutions between the 
CDV and neutralization resistant CDV mutant. a Genomic cDNA sequences of the two 
viruses were compared. Uniform length of 15,690 nt was achieved for each genomic 
cDNA after trimming sequence ends and assembly. b Nucleotide locations of genes and 
positions for nt changes in each gene are shown. c Amino acid coding substitutions 
caused by the nt changes are shown for each gene.        
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Figure 5. Mutation in F gene of the neutralization escape CDV isolate. A point mutation 
changed the tyrosine to serine at aa position 48 as highlighted in bold. The mutation 
locates in signal peptide region of CDV F. The signal peptide is from amino acid 1-135 
in precursor F protein (Plattet et al., 2007) and residues 1-50 are shown.   
 
 
 
Figure 6. Alignment of aa 501-547 of CDV H and corresponding regions in H proteins of 
MV,  rinderpest virus (P09460), peste des petits ruminants virus (PPRV AHA58209), 
dolphin morbillivirus (DMV Q66411) and phocine distemper virus (PDV P28882). Amino 
acid residues conserved among all 6 morbilliviruses are boxed. The CDV H is 607 aa in 
length and the point mutation changed Y to D at aa position 537 (pointed by the 
triangular arrow) in H of the neutralization-resistant mutant. This sequence corresponds 
to aa 505-551 in MV H (Masse et al., 2004), which is involved in H binding to MV 
receptors and is fully conserved among a variety of MV isolates including Edmonston, 
Schwarz, Moraten and Zagreb vaccine viruses (H protein sequence accession # in 
GenBank: P08362, AAA566657, CAL40872, and AM237414, respectively).  
